Ignite Creation Date:
2025-12-24 @ 2:13 PM
Ignite Modification Date:
2025-12-26 @ 2:37 AM
Study NCT ID:
NCT00964795
Status:
COMPLETED
Last Update Posted:
2015-03-23
First Post:
2009-08-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-12
Start Date Type:
None
Primary Completion Date:
2013-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-08
Completion Date Type:
ACTUAL
First Submit Date:
2009-08-20
First Submit QC Date:
None
Study First Post Date:
2009-08-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-08-28
Results First Submit QC Date:
None
Results First Post Date:
2015-03-23
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-03-10
Last Update Post Date:
2015-03-23
Last Update Post Date Type:
ESTIMATED